2024 Revenues ($USD) : $4.90B
Eisai demonstrated impressive Q3 2025 performance with revenue reaching JP¥216.1B, representing a 22% YoY increase, while net income surged 299% to JP¥23.8B. The Alzheimer's therapy Leqembi, developed with Biogen, remains on track to meet its ¥42.5B sales target for fiscal year 2024, though US adoption has been slower than anticipated. Eisai's revenue is forecast to grow 4.6% annually over the next three years, outpacing the Japanese pharmaceutical industry average.